Cardiovascular pharmacology focusing on the study of signal transduction pathways that mediate vasoconstriction and vasorelaxation. Techniques: Tissue/organ bath experiments, calcium assays, western blotting, toxicity assay using Caenorhabditis Elegans and metabolomics. 

Dr. Aznul Qalid Md Sabri currently holds the position of Associate Professor at the Department of Artificial Intelligence, Faculty of Computer Science & IT, Universiti Malaya. He was previously the Director of UM Centre of Innovation and Enterprise (UMCIE). In that role, he led a center that manages technology transfer, and the commercialization of research output for the entire of Universiti Malaya. Prior to that, he was appointed as the Head for the Department of Artificial Intelligence, Faculty of Computer Science and Information Technology (FCSIT), Universiti Malaya, Malaysia. During his tenure as the department head, he had led the establishment of Malaya AIR, which stands for the Malaya AI Research center. He is a graduate of the prestigious Erasmus Mundus Master in Vision and Robotics (ViBot), a Master program jointly coordinated by three different universities (University of Burgundy, France, University of Girona, Spain and Heriot-Watt University Edinburgh, United Kingdom). He then completed his Master's degree by performing a research internship program at the Commonwealth Scientific Research Organization (CSIRO) in Brisbane, Australia focusing on Medical Imaging. Next, he pursued his PhD on the topic of “Human Action Recognition” (completed with distinction, très honorable), under a program jointly offered by a well-known research institution in France, Mines de Douai (a research lab) and the reputable University of Picardie Jules Verne, Amiens, France. He is an active researcher in the field of Artificial Intelligence, having published in multiple international conferences as well as international journals. His main research interest is in the field of Computer Vision and Machine Learning especially the application of AI in Healthcare. Among the highlight of his research achievement is securing a bilateral collaboration with France through the Malaysia-France- Bilateral Research Collaboration 2021 (MATCH 2021)  grant. Through this grant, he is currently co-supervising a PhD student (with a French counterpart) that has published a paper on the usage of AI for emotion detection and estimation, that has potential usage for evaluating the emotional level of Autistic children. He is also active in research commercialization, having co-founded a UM spin-off company, Fylix Sdn. Bhd. (www.fylix.my). Fylix is an AI-based company that has delivered projects for government agencies such as the Malaysia Government Call Center (MyGCC) as well as large private corporations such as PETRONAS and the Employees Provident Fund (EPF) focusing on intelligent Chatbot solution as well as automating operations via AI. He is also instrumental in moving the faculty's business pod forward, FSKTM Technovations (https://technovations.com.my/), which has delivered multiple projects focused on system development as well as providing training and consultations for local and international companies such as Air Liquide, a French multi-national company.

Dr. Leong research focus on investigating the mechanism of action of potent compounds toward developing new anticancer and antidiabetes drugs. His research adopts an in vitro approach using cell-based and enzymatic assays to identify the various cellular pathways modulated by a potent compound. The research outcome is to understand the mechanism of action of the compound, a prerequisite requirement in developing a new drug entity. In addition, he employs metabolomics to evaluate biomarkers in explaining the treatment outcomes or disease progression. International collaboration has geared his research towards cancer stem cells and utilizing zebrafish as an animal model for cancer. It is believed that cancer stem cells is a subset of cells in tumour that drives chemoresistance and relapse in cancer patients. Therefore, strategies to develop new chemotherapy against the subset of cells is of great interest to tackle the problem.